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HYPERTENSION, DYSLIPIDEMIA,AND DIABETES AMONG
UNITED STATES ADULTS AGED 65 AND OLDER
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1Pﬁzer Inc, New York, NY, USA, 2Science Applications International
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OBJECTIVE: Hypertension, dyslipidemia, and diabetes, which
are established risk factors for cardiovascular disease (CVD),
have been previously described among adults aged 65 and older,
but have not been updated to reﬂect current national data. We
assess prevalence, awareness, treatment and control rates among
U.S. adults aged 65 and older with respect to hypertension,
dyslipidemia, and diabetes, and describe predictors associated
with awareness and management of these factors. METHODS:
Analysis of nationally representative data collected from adults
aged 65 and older (n = 3810) participating in the National
Health and Nutrition Examination Survey (NHANES) 1999–
2004. RESULTS: Women have a signiﬁcantly higher prevalence
of hypertension than men (76.6% vs 63.0%) and a signiﬁcantly
lower rate of control when treated pharmacologically (42.9% vs
57.9%). Dyslipidemia prevalence is 60.3% overall, and women
are signiﬁcantly more likely to be aware of their condition than
men (71.1% vs 59.1%). Diabetes affects 21.2% of older adults,
and 50.9% of prevalent cases are treated pharmacologically.
Goal attainment among those treated is problematic for all three
conditions–hypertension (48.8%), dyslipidemia (64.9%), and
diabetes (50.4%). Having two or more doctor visits annually is
associated with goal attainment for dyslipidemia. CONCLU-
SION: Knowledge of cardiovascular health in older adults and
understanding gender gaps in awareness can help physicians and
policymakers improve disease management and patient educa-
tion programs.
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SIGMOID MAXIMUM EFFECT MODELING OF CORONARY
HEART DISEASE DEATH AND MYOCARDIAL INFARCTION
RATEVERSUS LOW-DENSITY LIPOPROTEIN CHOLESTEROL
IN STATIN SECONDARY PREVENTIONTRIALS
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OBJECTIVE: Guidelines and expert opinion regard the relation-
ship between low-density lipoprotein cholesterol (LDL-C) and
coronary heart disease (CHD) event rates fromprevention trials as
linear or log-linear. However, these relationships require key
assumptions that are typically invalid in biological systems, and
may be more fully described by a sigmoidal maximum effect
function.METHODS:Data were extracted from statin secondary
prevention trials of at least 4-years duration (CARE, LIPID, 4S,
HPS, TNT, IDEAL; N = 57,042; average duration 5.2 yrs, range
4.8–6.1 yrs). Linear and modiﬁed nonlinear sigmoid maximum
effect (sEmax) models were constructed using WinNONLIN
(v.1.5, Pharsight Corporation, Mountain View, CA) to evaluate
the relationship of annualized absolute rates of CHD death
plus nonfatal myocardial infarction (NFMI) versus average
on-treatment LDL-C. Model output included E0 (CHD
death + NFMI %/yr at LDL-C = 0 mg/dL) and ﬁt parameters [r2
and Akaike’s Information Criteria (AIC)]. The model-dependent
number needed to treat (NNT) for one year to prevent one CHD
death + NFMI event with LDL-C reduction from 100 mg/dL to
70 mg/dL was also calculated. RESULTS: Fit parameters indi-
cated that the sEmax was the more correct model (r2 = 0.906,
AIC = 8.40; linear r2 = 0.876, AIC = 15.99). The sEmax model
yielded an E0 of 1.37%/yr, whereas the linear model E0 was
biologically implausible at –0.76%/yr. The CHD death + NFMI
rate at LDL-C = 100 mg/dL (sEmax 1.91%/yr; linear 2.13%/yr)
and LDL-C = 70 mg/dL (sEmax 1.58%/yr; linear 1.14%/yr)
resulted in NNT of 303 and 101 based on sEmax and linear
models, respectively. CONCLUSION: The relationship between
LDL-C and annualized rate of CHD death + NFMI is sigmoidal
and best described by a nonlinearmaximum effectmodel (sEmax).
Thismodel demonstrates amarked diminishing rate of returnwith
aggressive LDL-C lowering, strongly suggesting alternative risk
modiﬁcation measures be explored at LDL-C <100 mg/dL. These
ﬁndings have clinical trial design, treatment guideline, managed
care, economic, and public health implications.
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MEDICAL CLAIMS FOR GASTROINTESTINAL ADVERSE
EVENTS ARE COMMON IN PATIENTS PRESCRIBED
CLOPIDOGREL
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OBJECTIVE: Clopidogrel is commonly co-prescribed with
aspirin in patients with heart disease, and therefore the associ-
ated risk of gastrointestinal adverse events may be high. We
sought to determine the incidence of medical claims for potential
gastrointestinal adverse events among clopidogrel users in an
administrative database. METHODS: Clopidogrel users were
identiﬁed in a large US database (representing a network of over
70 managed care plans) based on the following criteria: an initial
clopidogrel prescription between between October 2003 and
January 2004, a clopidogrel-free window in the prior 6 months,
and at least 24 months of continuous eligibility over the study
time-frame. ICD9 codes were used to identify new peptic ulcer
and gastrointestinal bleeding events in the 12 months after the
ﬁrst clopidogrel prescription. RESULTS: There were 368,061
subjects identiﬁed who met the selection criteria. Of these sub-
jects, 58% were male and 72% were greater than or equal to 60
years of age. The average duration of clopidogrel use was 200
days. The proportion having a medical claim for peptic ulcer or
gastrointestinal bleeding was 6.2%. Higher incidences were seen
in women compared to men (7.4% vs. 5.4%; p < 0.000001) and
those who were greater than or equal to 60 years of age
compared to those under 60 (6.9% vs. 4.3%; p < 0.000001).
CONCLUSION: There is a high incidence of medical claims for
peptic ulcer or upper gastrointestinal bleeding among patients
who receive clopidogrel, especially in women and those who are
greater than or equal to 60 years of age.
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RETROSPECTIVE COHORT STUDY
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OBJECTIVE: Because of recent attention to public adverse event
reporting systems, we assessed ﬁndings from published case
reports and adverse drug reactions reported to the World Health
Organization (WHO) Programme for International Drug
Monitoring and ﬁndings from an analysis of patients in the
General Practice Research Database (GPRD) regarding bro-
mocriptine and risk of myocardial infarction and stroke (CVD).
METHODS: We tallied reports of adverse CVD events related to
bromocriptine in the medical literature using PubMed (years
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1950–2007) and from the WHO (years 1997–2006). Global
person-year exposure to bromocriptine was estimated using data
from IMS. Next, we conducted a retrospective matched cohort
study using data from the GPRD (years 1990–2006). Age- and
multivariate-adjusted Cox proportional hazard models were con-
structed to calculate a hazard ratio (HR) and 95% conﬁdence
interval (CI) of CVD events among bromocriptine users com-
pared to controls. RESULTS: We identiﬁed 24 CVD events pub-
lished in the worldwide medical literature and 56 CVD events
reported to the WHO over an estimated 19.3 million person-
years of bromocriptine exposure. At least 92% of reported CVD
events were among women in either data set. In our GPRD
cohort, 88% of patients exposed to bromocriptine for any
speciﬁed indication were women. After multivariate adjustment,
patients exposed to bromocriptine appeared to have lower risk of
a CVD event, although not statistically signiﬁcant, HR 0.82
(95% CI 0.29 to 2.31). Gender was not a signiﬁcant confounder
in the multivariate model. CONCLUSION: Using public report-
ing systems, CVD events appear to occur infrequently among
patients taking bromocriptine but predominately among women.
Results from our GPRD analysis are not consistent with an
increased risk of CVD events among patients taking bromocrip-
tine; rather, they suggest a decreased risk. These ﬁndings high-
light the need for careful epidemiologic study to consider the
potential risks associated with bromocriptine speciﬁcally and
medications in general.
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OBJECTIVE: Evaluate cardiovascular disease (CVD) outcomes
in managed care patients upon adherence to lipid treatment
guidelines [National Cholesterol Education Program’s Third
Report on Detection, Evaluation, and Treatment of High Blood
Cholesterol and Adult Treatment Panel’s (NCEP-ATP III)].
METHODS: Patients with laboratory values for low-density
lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C), & triglycerides (TG) between January 1,
2003-December 31, 2005 [index date], no lipid therapy
6-months pre-index date, and minimum 12 months health plan
eligibility pre- and post-index date were analyzed using the
HealthCore integrated managed care database. Patients were
classiﬁed as appropriately (AM) or inappropriately managed
(IAM) using baseline lipid levels and the ﬁrst post-index
follow-up lipid panel (goal attainment), and risk stratiﬁcation per
NCEP-ATP III guidelines. Impacts on lipid parameters between
groups were descriptively analyzed, while multivariate logistic
regression was performed to estimate risk of CVD events
(ischemic heart disease, peripheral vascular disease, stroke and
related occurrences and interventions). RESULTS: Among 8176
study patients (3493 AM; 4683 IAM), AM patients were signiﬁ-
cantly older [51.4  9.1 and 50.0  9.6 years, p < 0.01] and
comprised of fewer males (43.2% vs. 56.2%; p < 0.01). Mean
LDL-C, HDL-C, and TG baseline levels were signiﬁcantly differ-
ent among AM patients (127  35, 55  15, and 131  66 vs.
132  37, 45  13, and 181  81 respectively; p < 0.01).
During follow-up, AM patients had greater decreases in LDL-C
and TG levels versus IAM patients (-12% vs. –3% and –8% vs.
+5%; p < 0.01), while HDL-C levels showed greater increases
(5% vs. 2%; p < 0.01). AM patients were 38% less likely
to experience a CVD event versus IAM patients [Odds
Ratio = 0.62; 95% CI, 0.48–0.80; p < 0.01]. CONCLUSION:
Greater improvement in all three lipid parameters and reduction
in CVD event risk occurred among dyslipidemia patients
managed in accordance with clinical guideline treatment recom-
mendations in this managed care population.
CARDIOVASCULAR DISORDERS—Cost Studies
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OBJECTIVE: To assess the budget impact of reimbursing
aliskiren (Tekturna/Rasilez), the ﬁrst drug from a new class of
antihypertensive drugs (direct renin inhibitors), for the man-
agement of essential hypertension, from the health care payer
(RIZIV/INAMI), patient, and societal perspectives in Belgium.
METHODS: Following ISPOR’s budget impact guidelines, the
pharmacy costs of the current therapy distribution of patients
treated for essential hypertension in Belgium was compared to an
alternative scenario, where aliskiren gains market share from
conventional ARB therapy over a 3-year time horizon. IMS data-
bases and literature data were used to estimate the total number
of treated hypertensive patients and to derive market shares of
the different antihypertensive medication classes (Beta-blocker,
CCB, Diuretic, ACEi, ARB) and all possible dual and triple
combinations thereof. The antihypertensive market share uptake
of aliskiren was assumed to be identical to that observed previ-
ously for telmisartan in Belgium (0.16% year 1; 0.24% year 2;
and 0.28% year 3). Only drug acquisition costs (obtained from
ofﬁcial Tariffs) were considered in this analysis. Univariate sen-
sitivity analyses were performed as well as sub-populations
analyses. RESULTS: The predicted Belgian populations treated
for hypertension in 2008, 2009, and 2010 were estimated at
1,398,446 patients; 1,426,137 patients; and 1,525,827 patients,
respectively. Over 3 years, it was estimated that RIZIV/INAMI
hypertension drug budget following aliskiren reimbursement
would increase by 0.02% (i.e. €148,395), from €755,522,606 to
€755,671,001. Patients’ co-payments would decrease by
€20,613, resulting in societal incremental costs of €127,782.
Sensitivity analyses conﬁrmed that the net budget impact would
remain of the same magnitude. CONCLUSION: Our analyses
suggest that, under current assumptions, reimbursing aliskiren in
Belgium would only slightly increase costs from the RIZIV/
INAMI and societal perspectives, while generating savings for
patients. Moreover, this budget impact does not consider
aliskiren potential savings due to end organ protection.
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COST EFFECTIVENESS STUDIES IN HEART FAILURE:
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OBJECTIVE: Heart failure (HF) is a major public health burden
in terms of mortality, morbidity and costs. Economic analyses of
clinical trials and real-world studies have assessed the cost-
effectiveness of drugs used to treat HF. Although a few papers
have summarized the results of the earlier economic studies, new
evidence has emerged necessitating an update of the cost-
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